Clinical management of vitamin D deficiency requires distinguishing between native secosteroids and hydroxylated metabolites based on individual metabolic clearance and organ function. Cholecalciferol maintains superior pharmacokinetics over ergocalciferol due to higher hepatic CYP2R1 affinity, stronger vitamin D-binding protein avidity, and a longer half-life, resulting in more sustained serum 25-hydroxyvitamin D elevation. In patients with severe malabsorption, hepatic dysfunction, or acute deficiency, calcifediol offers direct intestinal absorption and rapid hepatic-independent repletion. Calcitriol and active analogs bypass renal CYP27B1 1-alpha-hydroxylation, making them strictly indicated for advanced chronic kidney disease, hypoparathyroidism, or specific metabolic bone disorders rather than nutritional deficiency.
Podden och tillhörande omslagsbild på den här sidan tillhör
Gurbir Gill, MD. Innehållet i podden är skapat av Gurbir Gill, MD och inte av,
eller tillsammans med, Poddtoppen.
